Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 153Lung Neoplasms 73Pancreatic Neoplasms 44Neoplasms 27Neoplasm Metastasis 25Head and Neck Neoplasms 23Brain Neoplasms 21Breast Neoplasms 18Glioblastoma 15Adenocarcinoma of Lung 15Squamous Cell Carcinoma of Head and Neck 14Gliosarcoma 14Adenocarcinoma, Bronchiolo-Alveolar 11Colorectal Neoplasms 10Glioma 9Carcinoma, Squamous Cell 8Carcinoma, Hepatocellular 8Adenocarcinoma 7Rectal Neoplasms 6Prostatic Neoplasms 6Esophageal Neoplasms 6Central Nervous System Neoplasms 6Carcinoma, Renal Cell 6Astrocytoma 6Oligodendroglioma 5Liver Neoplasms 5Colonic Neoplasms 5Carcinoma 5Recurrence 4Ovarian Neoplasms 4

Interventions

Sorafenib 3pazopanib 2Sunitinib 2eribulin 1Temozolomide 1Sirolimus 1Irinotecan 1Erlotinib Hydrochloride 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Refractory Solid Tumors × Erlotinib Hydrochloride × Clear all
NCT00759928 2014-07-02

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡